New insights in β-tubulin sequence analysis in non-small cell lung cancer

Lung Cancer

Volumn 41, Issue 1, 2003, Pages 41-48

  De Castro, J ^a   Belda Iniesta, C ^a   Cejas, P ^a   Casado, E ^a   Fresno Vara, J A ^a   Hardisson, D ^a   Sanchez J J ^b   Feliu, J ^a   Ordonez A ^a   Nistal, M ^a   Gonzalez Baron M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Chemotherapy; Non small cell lung cancer; Paclitaxel; Pseudogenes; Resistance; Tubulin

Indexed keywords

BETA TUBULIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ISOLATION; EXON; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INTRON; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0038460702     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00123-5     Document Type: Article

References (27)

1. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer, J. Clin. Oncol. 1997;15:2996-3018.
2. Parkin D.M., Pisan P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49:1999;33-64.
3. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18:2000;623-631.
4. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346:2002;92-99.
5. Isla D., Rosell R., Sánchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 19:2001;1071-1077.
6. Ginopoulos P., Kontomanolis E., Kardamakis D., et al. A phase II study of non-platinum-based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer. Lung Cancer. 38:2002;199-203.
7. Akerley W., Glantz M., Choy H., et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J. Clin. Oncol. 16:1998;153-158.
8. Dumontet C., Sikic B.I. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J. Clin. Oncol. 17:1999;1061-1070.
9. Nogales E., Wolf S.G., Downing K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature. 391:1998;199-202.
10. Burkhart C.A., Kavallaris M.B., Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta. 2:2001;1-9.
11. Monzó M., Rosell R., Sánchez J.J., et al. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J. Clin. Oncol. 17:1999;1786-1793.
12. Cabral F., Barlow S.B. Resistance to antimitotic agents as genetic probes of microtubule structure and function. Pharmacol. Ther. 52:1991;159-171.
13. Barlow S.B., Gonzalez-Garay M.L., Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J. Cell Sci. 115:2002;3469-3478.
14. Snyder J.P., Nettles J.H., Cornett B., Downing K.H., Nogales E. The binding conformation of taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. USA. 98:2001;5312-5316.
15. Wilde C.D., Crowther C.E., Cowan N.J. Diverse mechanisms in the generation of human beta-tubulin pseudogenes. Science. 217:1982;549.
16. Lee M.G., Lewis S.A., Wilde C.D., Cowan N.J. Evolutionary history of a multigene family: an expressed human beta-tubulin gene and three processed pseudogenes. Cell. 33:1983;477-487.
17. Kelley M.J., Li S., Harpole D.H. Genetic analysis of the β-tubulin gene, TUBB, in non-small cell lung cancer. J. Natl. Cancer Inst. 93:2001;1886-1888.
18. Tsurutani J., Komiya T., Uejima H., et al. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer. 35:2002;11-16.
19. Kohonen-Corish M.R., Oin H., Daniel J.J., et al. Lack of beta-tubulin gene mutations in early stage lung cancer. Int. J. Cancer. 101:2002;398-399.
20. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
21. De Castro J., Belda C., Cejas P., et al. Beta-tubulin mutations in non-small cell lung carcinoma (NSCLC): relationship with response to weekly paclitaxel and survival. Proc. Am. Soc. Clin. Oncol. 21:2002;2726. [Abstract].
22. Sale S., Sung R., Shen P., et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol. Cancer Ther. 1:2002;215-225.
23. Sale S., Oefner P.J., Sikic B.I. Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small cell lung cancer. J. Natl. Cancer Inst. 94:2002;776.
24. Feliu J., Martin G., Lizon J., et al. Sequential therapy in advanced non-small cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine: a phase II study. Ann. Oncol. 12:2001;1369-1374.
25. Van Geel M., van Deutekom J.C., Van Staalduinen A., et al. Identification of a novel beta-tubulin subfamily with one member (TUBB4Q) located near the telomere of chromosome region 4q35. Cytogenet. Cell Genet. 88:2000;316-321.
26. Puget N., Gad S., Perrin-Vidoz L., et al. Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am. J. Hum. Genet. 70:2002;858-865.
27. Mighell A.J., Smith N.R., Robinson P.A., Markham A.F. Vertebrate pseudogenes. FEBS Lett. 468:2000;109-114.